Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminocamptothecin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma
NCT00003523Phase 2
Key facts
- Status
- Completed
- Start
- Jan 1999
- Countries
- 2
- Sponsor
- GOG Foundation
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Drugs
- 9-aminocamptothecin
- Conditions
- ovarian cancerprimary peritoneal carcinoma (PPC)
01
Overview
Phase 2, open-label, single-arm trial of 9-aminocamptothecin in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Primary endpoints: Antitumor activity and Nature and degree of toxicity. Started Jan 1999; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Aminocamptothecin
Aminocamptothecin colloidal dispersion IV
03
Who it enrols
Patients with recurrent or persistent ovarian epithelial cancer or primary peritoneal carcinoma who have progressed on platinum-based treatment, with adequate organ function and no recent prior therapies.
04
Endpoints
Primary
Antitumor activity
Nature and degree of toxicity
Beyond the preview
Go deeper on NCT00003523.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003523.